CellCentric Initiates DOMMINO-1, a Pivotal Phase 2 Clinical Trial of Inobrodib in Combination with Pomalidomide and Dexamethasone (InoPd) in Relapsed or Refractory Multiple Myeloma

Key Takeaways

• Phase 2 DOMMINO‑1 enrolls 100 RRMM patients
• Inobrodib 20 mg combined with pomalidomide/dexamethasone
• Prior data showed 60% objective response rate
• Targets patients refractory to pomalidomide and BCMA agents
• All‑oral regimen may improve community‑setting accessibility

Summary

CellCentric has launched the pivotal Phase 2 DOMMINO‑1 trial of inobrodib 20 mg combined with pomalidomide and dexamethasone (InoPd) in heavily pretreated relapsed or refractory multiple myeloma (RRMM) patients. The first dose was administered at The Royal Marsden in London, with additional sites now open in the UK and the United States, targeting enrollment of 100 participants. Earlier dose‑optimization work reported a 60% objective response rate and tolerability comparable to pomalidomide‑dex alone. The study’s primary endpoint is overall response rate, with secondary measures of progression‑free and overall survival.

Pulse Analysis

The multiple myeloma landscape has shifted dramatically over the past two decades, moving from single‑agent chemotherapy to complex regimens that include proteasome inhibitors, anti‑CD38 antibodies, and bispecific antibodies. Yet, a sizable subset of patients eventually becomes refractory to these options, especially after exposure to BCMA‑targeted therapies. Oral agents that can be administered at home are increasingly valued for their convenience and potential to reduce hospital visits, a factor that resonates strongly in community oncology settings where more than 70% of myeloma care occurs.

Inobrodib’s first‑in‑class inhibition of the p300/CBP epigenetic regulator introduces a novel mechanism distinct from existing myeloma drugs. Early dose‑optimization studies demonstrated a 60% objective response rate when paired with standard pomalidomide‑dex, and safety data suggested no added toxicity beyond the backbone regimen. The FDA’s Fast Track and Orphan Drug designations underscore the therapeutic promise for a disease with high unmet need. DOMMINO‑1’s open‑label, single‑arm design will generate pivotal efficacy signals, focusing on overall response rate while also tracking progression‑free and overall survival.

If the trial confirms the preliminary activity, CellCentric could secure a differentiated, all‑oral option that competes with injectable bispecifics and CAR‑T therapies. Such a product would appeal to both patients seeking convenience and payers looking to lower infusion‑related costs. Moreover, the company’s broader pipeline—exploring inobrodib with other bispecifics and in maintenance settings—positions it to leverage combination strategies that could further expand market share. Investors are likely to watch the upcoming data closely, as successful outcomes could catalyze partnership discussions and elevate CellCentric’s valuation in the competitive myeloma space.